FGFelix Grignon
Felix Grignon
*This is an algorithmically generated author record based on publicly available information.
Research Subjects
Research Interests
Felix Grignon has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Ann Lee
Prime Medicine, Cambridge, Massachusetts, USA
1 shared publicationAudrey Le
International Society for Cell & Gene Therapy, Vancouver, British Columbia, Canada
1 shared publication- Bambi J. Grilley
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas, USA; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
1 shared publication - Beth E. Roxland
Roxland Consultants Ltd, New York, New York, USA
1 shared publication - Bruce L. Levine
Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, USA
1 shared publication - David R. Liu
Dana-Farber Cancer Institute, Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
- 24 June 2025
- Published by Elsevier in Cytotherapy
- Vol. 27 (10) , 1151-1163
Advancing gene-editing platforms to improve the viability of rare-disease therapeutics: key insights from a 2024 Scientific Exchange hosted by ARM, ISCT, and Danaher
- 24 June 2025
- Published by Elsevier in Cytotherapy
- Vol. 27 (10) , 1151-1163
Open AccessAdvancing gene-editing platforms to improve the viability of rare-disease therapeutics: key insights from a 2024 Scientific Exchange hosted by ARM, ISCT, and Danaher
- Open Access
- 7 February 2025
- Published by Elsevier in Cytotherapy
- Vol. 27 (6) , 671-677
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-based interventions
- 7 February 2025
- Published by Elsevier in Cytotherapy
- Vol. 27 (6) , 671-677
Open AccessInternational Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-based interventions